Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of RGH-706 in Prader-Willi syndrome
2021-004262-35Phase 2Active
- Sponsor
- Gedeon Richter Plc
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rgh-706 in Prader-Willi syndrome (PWS) (4 arms), sponsored by Gedeon Richter Plc. Started Apr 2022; status: active.
02
Drugs
rgh-706
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2021-004262-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004262-35.